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Abstract: Background: Exposure to intermittent hypoxia has been demonstrated to be an efficient
tool for hypoxic preconditioning, preventing damage to cells and demonstrating therapeutic benefits.
We aimed to evaluate the effects of respiratory intermittent hypobaric hypoxia (IHH) to avoid brain
injury caused by exposure to acute severe hypoxia (ASH). Methods: biomarkers of oxidative damage,
mitochondrial apoptosis, and transcriptional factors in response to hypoxia were assessed by Western
blot and immunohistochemistry in brain tissue. Four groups of rats were used: (1) normoxic (NOR),
(2) exposed to ASH (FiO2 7% for 6 h), (3) exposed to IHH for 3 h per day over 8 days at 460 mmHg,
and (4) ASH preconditioned after IHH. Results: ASH animals underwent increased oxidative-stress-
related parameters, an upregulation in apoptotic proteins and had astrocytes with phenotype forms
compatible with severe diffuse reactive astrogliosis. These effects were attenuated and even prevented
when the animals were preconditioned with IHH. These changes paralleled the inhibition of NF-κB
expression and the increase of erythropoietin (EPO) levels in the brain. Conclusions: IHH exerted
neuroprotection against ASH-induced oxidative injury by preventing oxidative stress and inhibiting
the apoptotic cascade, which was associated with NF-κB downregulation and EPO upregulation.
Keywords: apoptosis-inducing factor; erythropoietin; glial fibrillary acidic protein; glutathione; HIF;
NF-κB; superoxide dismutase
1. Introduction
The mammalian brain requires a continuous supply of oxygen to maintain its structure
and properly develop its function. When undergoing hypoxia, brain cells may remodel,
became injured or die depending on the severity and duration of the hypoxic insult. Thus,
the brain cannot tolerate a significant reduction in partial pressure of oxygen (PO2) for
long periods due to the inability of the anaerobic glycolysis metabolic pathway to provide
enough energy supply [1]. Since only the oxidative metabolism can provide the high-
energy demands required by brain cells, a continuous supply of oxygen and glucose is
needed, making the brain a very sensitive organ PO2 reductions, such as in conditions of
respiratory hypoxia [2,3]. However, sublethal hypoxic conditions stimulate neurogenesis
and angiogenesis by the secretion of trophic factors [4], as has been described during
embryonic brain development, where oxygen concentrations ranging from 1% to 5% allow
the CNS cells to differentiate and proliferate, indicating that under certain circumstances,
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hypoxia plays an important role in neurogenesis, neuroprotection and neuronal survival [5].
In fact, it is known that brief hypoxia exposures can elicit neuroprotection by enhancing
the tolerance of the exposed organism to ischemia [6] or severe hypoxia (see for review [7]).
Brain preconditioning is a phenomenon by which repeated doses of a stressful sublethal
stimulus protect the brain against subsequent injury. Intermittent hypoxia, i.e., repeated
episodes of hypoxia interspersed with episodes of normoxia, is a form of preconditioning
widely used to induce neuroprotection against severe hypoxia and ischemia [8]. Although
both in hypoxia and ischemia, oxygen deficiency is a common factor, ischemia is a hypoxic
episode characterized by insufficient nutrient supply due to decreased perfusion. In con-
trast, respiratory hypoxia involves decreased oxygen concentration in the tissue without
affecting blood flow and nutrient supply [9]. The effects of preconditioning on the expres-
sion of antioxidants and apoptosis-related factors have been studied extensively in cerebral
ischemia (see, for example, [10,11]), but few studies have addressed the effects of hypoxic
preconditioning after respiratory hypobaric hypoxia in the brain [12–15]. Hypoxic precon-
ditioning and its involved adaptive factors are interesting because hypoxia is at the base
of the pathogenesis of many diseases, and preventing damage to cells by inducing milder
processes that cause it could have several therapeutic benefits. Several uses of hypoxic
preconditioning have been proposed. For example, to protect the neonatal brain, which
is susceptible to hypoxic–ischemic injury due to its developmental characteristics [16]; to
act against ischemic cell death that takes place in stroke [17], or to be used in preoperative
interventions [9].
Hypoxic preconditioning could induce its neuroprotective action by triggering several
mechanisms, such as enhancing vascular regulation, the activation of antiapoptosis and
antioxidant signaling pathways, the suppression of excitotoxicity and the promotion of
cell proliferation [16]. The hypoxia-inducible factor (HIF) has emerged as the master tran-
scriptional regulator of oxygen homeostasis, controlling the expression of multiple genes,
including those that encode erythropoietin (EPO) and other proteins involved in red blood
cell production and, thus, increasing blood oxygen-carrying capacity that may contribute
to hypoxia-induced tolerance [18]. Moreover, over the last few years, a neuroprotective
role for EPO has been described. It has been shown that in neurons, the binding of EPO to
its receptor leads to the activation of several signaling pathways ending in transcription
factors that move to the nucleus and initiate the expression of Bcl-2 and Bcl-xL genes [19].
These proteins play a pivotal role in counteracting the activation of proapoptotic proteins
by regulating the permeabilization of the mitochondrial outer membrane and consequently
the release of cytochrome c into cytoplasm and the mitochondrial intrinsic apoptotic path-
way [20]. The response to hypoxia is not only based on HIF since many other transcription
factors have shown a response to hypoxia [21]. Among these is the transcription factor
family Nuclear Factor-κB (NF-κB) formed by five different proteins that can diversely com-
bine to form an active transcriptional dimer implicated in regulating cellular proliferation,
inflammatory response, cell apoptosis and cell survival [22,23]. Oxidative stress that results
from hypoxia exposure also plays an important role in the activation of NF-κB [21,24].
Recently, some evidence has been provided about the function of astrocytes as specialized
CNS sensors for detecting physiological decreases in brain oxygenation [25]. The detection
of low PO2 by these cells would stimulate the neurons that contribute to the respiratory
response to hypoxia and increase the oxygenation of the arterial blood. Additionally,
astrocytes are believed to release vasoactive substances, significantly affecting cerebral
vasculature by controlling local cerebral microcirculation at low PO2 [26].
The present work aimed to evaluate the effects of an intermittent hypobaric hypoxia
preconditioning protocol (4 h/day for 8 days at 460 mmHg) on brain injury caused by
exposure to acute severe normobaric hypoxia (6 h at 7% FiO2), analyzing the pro-oxidant
and antioxidant system, mitochondrial apoptotic markers, levels of hypoxia transcriptional
factors, EPO and astrocyte’s morphology and reactivity in the brains of rats.
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2. Results
2.1. Oxidative Stress
Exposure to ASH generated increased oxidative stress that led to significantly (p <
0.001) higher levels of lipid (thiobarbituric acid reactive substances, TBARS) and protein
oxidation (advanced oxidation protein products, AOPP) and nitric oxide species (NOx)
(Figure 1). This increase was prevented in IHH and IHH+ASH, showing a statistically
significant reduction compared to ASH. Antioxidant enzymes, such as superoxide dismu-
tase (SOD) and reduced glutathione (GSH), decreased significantly in ASH and recovered
in both groups exposed to intermittent hypoxia (Table 1). Reduced glutathione (GSH)
decreased significantly in all hypoxia-exposed groups, and oxidized glutathione (GSSG)
showed no statistical differences between the groups. However, the greater significant
decrease in GSH combined with the non-significant increase in GSSG resulted in a statisti-
cally significant decrease (p < 0.001) in GSH/GSSG ratio in ASH. This ratio did not show
significant differences either in IHH or in IHH+ASH when compared to NOR. Glutathione
peroxidase (GPx) was reduced in all the hypoxic groups, especially in those exposed to
intermittent hypoxia, which presented statistically significant differences not only to NOR
but also to ASH. Glutathione reductase (GR) decreased significantly due to the ASH insult,
which was prevented both in IHH and IHH+ASH groups.
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Table 1. Antioxidant activity and gluthatione system in the brain. 
 NOR ASH IHH IHH+ASH 
Glutathione     
GSH (nmol·mg−1) 1.60 ± 0.11 1.08 ± 0.04 ** 1.26 ± 0.07 * 1.19 ± 0.11 * 
GSSG (nmol·mg−1) 0.90 ± 0.10 1.11 ± 0.06 0.88 ± 0.02 1.04 ± 0.12 
GSH/GSSG 1.63 ± 0.05 0.94 ± 0.10 *** 1.43 ± 0.04 1.35 ± 0.13 
Enzymes     
GPx (µU·mg−1) 15.4 ± 0.93 13.0 ± 0.49 * 8.3 ± 0.93 *** +++ 10.4 ± 0.62 *** ++ 
GR (µU·mg−1) 6.47 ± 0.50 4.28 ± 0.45 ** 5.51 ± 0.28 + 6.02 ± 0.53 ++ 
SOD (U·mg−1) 1.52 ± 0.12 1.10 ± 0.05 * 1.30 ± 0.10 1.45 ± 0.12 
Figure 1. Oxidative stress markers in the brain. Units are expressed per milligram of protein. (A) TBARS, thiobarbituric
acid-reactive substances; (B) AOPP, advanced oxidation protein products; and (C) NOx, nitric oxide species. Statistically
significant differences between groups are presented with asterisks (*, vs. NOR) or crosses (+, vs. ASH). Two symbols
indicate p < 0.01 and three symbols p < 0.001. F-values after running one-way ANOVAs with Bonferroni’s post hoc
multiple comparison tests were: F = 10.83 (TBARS), F = 12.42 (AOPP) and F = 6.33 (NOx). Animal experimental groups are
abbreviated as NOR, normoxic; ASH, acute severe hypoxia; IHH, intermittent hypobaric hypoxia; IH +ASH, intermittent
hypobaric hypoxia followed by acut severe hypoxia.
a le 1. tioxi a t activity a gl t atio e syste i t e brai .
NOR ASH IHH IHH+ASH
Glutathione
GSH (nmol·mg−1) 1.60 ± 0.11 1.08 ± 0.04 ** 1.26 ± 0.07 * 1.19 ± 0.11 *
GSSG (nmol·mg−1) 0.90 ± 0.10 1.11 ± 0.06 0.88 ± 0.02 1.04 ± 0.12
GSH/GSSG 1.63 ± 0.05 0.94 ± 0.10 *** 1.43 ± 0.04 1.35 ± 0.13
Enzymes
GPx (µU·mg−1) 15.4 ± 0.93 13.0 ± 0.49 * 8.3 ± 0.93 ***+++
10.4 ± 0.62 ***
++
GR (µU·mg−1) 6.47 ± 0.50 4.28 ± 0.45 ** 5.51 ± .28 + 6 02 53 ++
SOD (U·mg−1) 1.52 ± 0.12 1.10 ± 0.05 * 1.30 ± 0.10 1.45 ± 0.12
GPx, glutathione peroxidase; GSH, reduced glutathione; GSSG, oxidized glutathione; GR, glutathione reductase;
SOD, superoxide dismutase. Values are means ± SEM. Statistically significant differences between groups are
presented with asterisks (*, vs. NOR) or crosses (+, vs. ASH). One symbol indicates p < 0.05, two symbols p <
0.01 and three symbols p < 0.001. F-values after running one-way ANOVAs with Bonferroni’s post hoc multiple
comparison tests were: F = 8.02 (GSH), F = 1.39 (GSSG), F = 11.80 (GSH/GSSG), F = 15.06 (GPx), F = 4.33 (GR) and
F = 3.31 (SOD). Animal experimental groups are abbreviated as: NOR, normoxic; ASH, acute severe hypoxia; IHH,
intermittent hypobaric hypoxia; IHH+ASH, intermittent hypobaric hypoxia followed by acute severe hypoxia.
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2.2. Mitochondrial Apoptosis
The measured mitochondrial apoptosis indicators, i.e., cytochrome c, apoptosis-
inducing factor (AIF) and active caspase-3, showed significant increases in ASH, as indi-
cated by Western blot semi-quantification (Figure 2). However, cytochrome c (Figure 2A)
and active caspase-3 (Figure 2C) expression were similar to NOR levels in both IHH and
IHH+ASH groups, having statistically significant lower levels when compared to ASH.
The slight decrease in AIF was not statistically significant (Figure 2B).
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2.5. Astrocytes 
Figure 4 shows representative immunohistochemical slides from the Cornus ammonis 
CA1 hippocampus region stained for glial fibrillary acidic protein (GFAP). The quantita-
tive analysis of the astrocyte morphology (soma areas and processes length) and the in-
tensity of GFAP immunoreactivity are summarized in Figure 5. Exposure to acute severe 
respiratory hypoxia caused a severe diffuse reactive astrogliosis in ASH. Astrocytes from 
this group evidenced significant changes in their morphology with hypertrophy of the 
cellular bodies (larger soma areas) and retraction of the cellular extensions (shorter cell 
processes length) when compared to NOR astrocytes (Figures 4F,J–L and 5A). Moreover, 
ASH astrocytes had a significant increase in GFAP protein immunoreactivity (Figure 5B). 
These morphological changes and immunoreactivity patterns did not appear in animals 
exposed to intermittent hypobaric hypoxia. In these animals, the soma areas (Figure 5A) 
and the expression of astrocyte GFAP immunoreactivity were significantly decreased 
(Figure 5B) together with a proliferation of the cellular processes compared with NOR 
(Figures 4 and 5A). Thus, preconditioning by intermittent hypoxia (IHH+ASH) reduced 
the astrogliosis intensity caused by severe respiratory hypoxia compared to (ASH). 
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corresponding well) are shown. Units are expressed relative to the β-actin content. (A) HIF-1α, hypoxia-inducible factor
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2.4. Erythropoietin (EPO) Expression in the Brain
Figure 3C shows the EPO levels in the brains of the four groups of rats. It can be
seen that all hypoxia-exposed animals had higher statistically significant concentrations of
EPO. The greatest EPO response to hypoxia was observed in IHH+ASH, which showed an
additive effect to IHH and ASH exposure. Statistically significant differences were observed
between all groups showing an accumulative effect from ASH, IHH to IHH+ASH.
2.5. Astrocytes
Figure 4 shows representative immunohistochemical slides from the Cornus ammonis
CA1 hippocampus region stained for glial fibrillary acidic protein (GFAP). The quanti-
tative analysis of the astrocyte morphology (soma areas and processes length) and the
intensity of GFAP immunoreactivity are summarized in Figure 5. Exposure to acute se-
vere respiratory hypoxia caused a severe diffuse reactive astrogliosis in ASH. Astrocytes
from this group evidenced significant changes in their morphology with hypertrophy of
the cellular bodies (larger soma areas) and retraction of the cellular extensions (shorter
cell processes length) when compared to NOR astrocytes (Figure 4F,J–L and Figure 5A).
Moreover, ASH astrocytes had a significant increase in GFAP protein immunoreactivity
(Figure 5B). These morphological changes and immunoreactivity patterns did not appear
in animals exposed to intermittent hypobaric hypoxia. In these animals, the soma areas
(Figure 5A) and the expression of astrocyte GFAP immunoreactivity were significantly
decreased (Figure 5B) together with a proliferation of the cellular processes compared
with NOR (Figures 4 and 5A). Thus, preconditioning by intermittent hypoxia (IHH+ASH)
reduced the astrogliosis intensity caused by severe respiratory hypoxia compared to (ASH).




Figure 4. Glial fibrillary acidic protein (GFAP) immunohistochemistry in the Cornu ammonis (CA1) hippocampal zone at 
different magnifications. The increase in GFAP expression and changes in astrocyte morphology is more pronounced in 
ASH (B,F,J,K,L). Animals exposed to IHH had greater GFAP expression but did not show astrogliosis (C,D,G,H). Bars 
represent the following distances: ((A)–(D)), 100 µm; ((E)–(H)), 40 µm; ((I)–(J)), 20 µm; ((K)–(L)), 15 µm. Animal experi-
mental groups are abbreviated as NOR, normoxic; ASH, acute severe hypoxia; IHH, intermittent hypobaric hypoxia; 
IHH+ASH, intermittent hypobaric hypoxia followed by acute severe hypoxia. 
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(B) expression of astrocyte glial fibrillary acidic protein (GFAP) immunoreactivity. All data were 
obtained in the Cornu ammonis (CA1) hippocampal zone. The box represents the interquartile 
range in the box-and-whisker plots and shows the first and third quartiles separated by the me-
dian. The black dot represents the mean, and whisker endpoints represent the minimum and max-
imum values. Statistically significant differences between groups are presented with asterisks (*, 
vs. NOR) or crosses (+, vs. ASH). The three symbols indicate p < 0.001. F-values after running one-
way ANOVAs with Bonferroni’s post hoc multiple comparison tests were: F = 85.94 (soma area), F 
= 119.93 (process length) and F = 20.77 (GFAP immunoreactivity). Animal experimental groups are 
Figure 4. Glial fib illary acidic protein (GFAP) immunohistochemistry in the Cornu ammonis (CA1)
hippocampal zone at different magnifications. The increase in GFAP expression and changes in
astr cyte morphology is more pronounced in ASH (B,F,J,K,L). Animals exposed to IHH had greater
GFAP expression but did not show astrogliosis (C,D,G,H). Bars represent the following distances:
((A)–(D)), 100 µm; ((E)–(H)), 40 µm; (I,J), 20 µm; (K,L), 15 µm. Animal experimental groups are
abbreviated as NOR, normoxic; ASH, acute severe hypoxia; IHH, intermittent hypobaric hypoxia;
IHH+ASH, intermittent hypobaric hypoxia followed by acute severe hypoxia.
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intermittent hypobaric hypoxia followed by acute severe hypoxia.
3. Discussion
We investigated the effects on the brain of a preconditioning protocol of exposure
to intermittent hypobaric hypoxia before an acute severe normobaric hypoxia insult. In
summary, the results show that: (1) exposure to ASH caused oxidative stress in the brain,
as demonstrated by significant increases in lipid and protein oxidation and the NOx levels;
a drop in the antioxidant capacity, as indicated the significant decrease in SOD activity,
GSH levels and GSH/GSSG ratio; and activated the mitochondrial apoptotic pathway,
as shown by the significant boost of cytochrome c, AIF and caspase-3 expression; (2) a
protocol of IHH before exposure to ASH prevented these deleterious effects avoiding
oxidative stress and maintaining the antioxidant capacity and the apoptotic markers at
baseline (NOR) conditions; (3) the expression of HIF-1α and EPO in the brain of all groups
exposed to hypoxia increased significantly when compared to NOR, both acute-exposed
and preconditioned animals presenting similar values for HIF-1α, but the preconditioned
group (IHH+ASH) having significantly higher EPO expression than the ASH- or IHH-
exposed groups; (4) in contrast to this behavior, the significant increase found in NF-
κB levels after ASH exposure was prevented by the IHH protocol; (5) ASH induced in
hippocampus astrocytes’ morphology changes compatible with severe diffuse reactive
astrogliosis, while IHH+ASH reduced the astrogliosis intensity to mild to moderate and
increased GFAP expression compared to NOR.
3.1. Oxidative Stress
Brains from rats exposed to severe hypoxia (ASH) increased their oxidant activity
leading to the oxidation of lipids (TBARS), proteins (AOPP) and nitric oxide species (NOx)
(Figure 1). This was concomitant with decreased antioxidant activity as the decrease of
SOD and GR activities and the ratio GSH/GSSG indicated (Table 1). All these results
conform to a situation of oxidative distress [27] and are coincident with previous results
from our group [28] and with findings reported by others [29–31].
Under normoxic conditions, the combined action of antioxidants and oxidants main-
tains the homeostasis of free radicals. Since cell survival depends on strict regulation of
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the free radical content, an excess of free radicals leads to a situation of oxidative distress,
while a deficit of free radicals (specifically hydrogen peroxide) leads to oxidative eustress,
which may affect important cellular signaling pathways [32]. Neurons obtain ATP primar-
ily through oxidative phosphorylation via the mitochondrial electron transport chain, a
process where it is a continuous production of the radical superoxide (O2−). This radical
is maintained within homeostatic levels by antioxidant systems, such as SOD [33,34]. Se-
vere hypoxia affects the process of mitochondrial oxidative phosphorylation leading to
increased production of O2− [35] and decreased antioxidant capacity elicited by SOD and
GR [36]. SOD functions keeping the O2− homeostatic levels generating H2O2, which is
converted to H2O by oxidation of GSH to GSSG through a concerted cascade of mecha-
nisms involving GPx and GR [37]. Our results show that exposure to severe hypoxia (ASH)
caused decreased SOD and GSH and increased GSSG, resulting in a decreased GSH/GSSG
ratio (Table 1). Under normoxic conditions, this ratio is maintained by the action of GR and
is decreased in hypoxia [29]. Thus, the increased production of reactive oxygen species
(ROS) coupled with the decrease in SOD observed in our study in ASH implies that a
fraction of the O2− is not reduced to H2O2. In the same way, the decreased levels of GSH
may be insufficient to reduce the H2O2 to H2O, leading to a buildup of H2O2. These
conditions derive from an accumulation of O2− and H2O2, which can, respectively, react
either with NO−, forming peroxynitrite (ONOO−) or with ferrous ion (Fe2+) rendering
−OH and Fe3+ (Fenton reaction) [38]. Both ONOO− and −OH are highly reactive radicals,
which explain the presence of oxidized forms of lipids and proteins that we have found in
the brains of the ASH rats (Figure 1).
Our results show that the above-mentioned oxidative stress caused by the acute
exposure to severe hypoxia was inhibited when the animals were previously exposed to a
protocol of intermittent hypobaric hypoxia. IHH+ASH animals had a level of oxidation of
lipids and proteins and the presence of NOx similar to the NOR group, with significantly
lower values than ASH (Figure 1). Moreover, the antioxidant activity of SOD, GR, and the
ratio GSH/GSSG did not differ from those observed in the brains of NOR rats (Table 1),
indicating that the preconditioning protocol of intermittent hypoxia had a neuroprotective
effect by preventing oxidative distress. Similar results were obtained by Stroev et al. [15]
using a shorter hypoxic preconditioning protocol and exposing the animals to a more
severe acute hypoxia. However, the present study additionally shows that preconditioning
elevated SOD levels without a period of reoxygenation after IHH+ASH. As a future
perspective to confirm these findings, it would be interesting to analyze protein or mRNA
abundance of catalase and peroxidase since ROS damage caused by H2O2 can be mitigated
by these enzymes. Additionally, to analyze some electron transport chain complex subunits
(e.g., complex I or complex III) would also be particularly interesting due to the high
mitochondrial sensibility to hypoxia.
There is concluding evidence that oxidative stress is linked to several neuropathologi-
cal processes involving specific mitochondrial targets [39], suggesting that the mitochondria
could be the main cell sites where brain damage produced by severe acute hypoxia expo-
sure would act. In fact, under hypoxic conditions, mitochondria are the major source of
ROS [40,41], and it is well-known that hypoxia alters mitochondrial function by affecting
the oxidative phosphorylation due to decreased electron transport rate, a reduction of the
mitochondrial membrane potential (∆ψm), and an enhanced nitric oxide synthase [42–44].
Furthermore, the mitochondria can be targeted by their own radicals [45], and in turn, ROS
and reactive nitrogen species can interact to form peroxynitrite, affecting the function of key
enzymes, such as mitochondrial complex I and resulting in less ATP production [39]. This
complex interplay between oxidative stress and mitochondrial dysfunction may lead to a
mechanism that activates the proapoptotic cascade. Thus, we aimed to determine if precon-
ditioning, demonstrating prevention of oxidative stress, would also prevent mitochondrial
apoptosis.
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3.2. Mitochondrial Apoptosis
Levels of mitochondrial apoptosis markers, such as cytochrome c, AIF and active
caspase-3, showed a significant increase in the brains of rats exposed to ASH (Figure 2). In
contrast, when ASH was preceded by IHH exposure (IHH+ASH), the levels of cytochrome
c and active caspase-3 did not differ from those found in normoxic rats. This antiapoptotic
behavior induced by IHH preconditioning matches the prevention of oxidative stress
markers, suggesting that prevention of oxidative stress in IHH and IHH+ASH groups
also avoided mitochondrial dysfunction and apoptosis. Some explanation to the neuronal
protective mechanisms involved after hypoxic preconditioning could be derived from a
work that analyzed immunohistochemically the patterns of expression of antiapoptotic
proteins Bcl-2 and Bcl-xL in rat hippocampus and neocortex after three sessions of IHH [13],
where it was concluded that the protective action was in part mediated by the shift of
neuronal Bax/Bcl-2-Bcl–xL ratio.
Contrasting with the results obtained for cytochrome c and caspase-3, we did not
find significant differences in AIF levels between IHH and IHH+ASH groups and ASH
(Figure 2B), suggesting that AIF was not involved in the mechanisms of neuroprotection
induced by IHH. Since AIF has been described as a neuroprotective factor in the processes
of excitotoxicity [46], our results suggest that the harmful effect caused by ASH in the
brain is not associated with excitotoxicity, as is in the case of ischemic hypoxia. This
conclusion agrees with other studies [47,48], reinforcing the idea that, although hypoxia is
the determining factor in both severe respiratory hypoxia and ischemic hypoxia, respiratory
hypoxia induces different responses in the brain from those induced by ischemic hypoxia.
3.3. Transcriptional Factors in Response to Hypoxia
The expression of HIF-1α increased in the brain of all the groups exposed to hypoxia
compared to the normoxic group (Figure 3A), with no significant differences between
animals exposed to ASH and those exposed to IHH+ASH. Since ASH caused significant
oxidative stress, while preconditioning with IHH did not, the expression of HIF-1α seems
independent of the presence of a state of oxidative stress in the brain, although it has been
described that free radicals induced by hypoxia stabilize HIF-1α [49,50]. In any case, our
results indicate that HIF-1α does not play an important role in preconditioning processes
induced by IHH.
NF-κB had a similar type of behavior to HIF-1α in ASH rats, presenting a significant
increase in the expression of its phosphorylated p50 subunit (Figure 3B). This increased
expression of NF-κBp50 in response to exposure to severe hypoxia was already observed
in previous work from our laboratory [28] and reported by others [22,51]. However,
contrasting with HIF-1α, in the brains of IHH-exposed rats, the expression of NF-κB did
not differ from the levels found in the brains of normoxic rats. Thus, there is a different
type of behavior in response to hypoxia between HIF-1α and NF-κB since IHH interferes
with the activation mechanisms of the NF-κBp50 subunit, but not with those of HIF-1α
expression. Overall, these results indicate that the decrease in NF-κB in the brain of IHH
and IHH+ASH rats was associated with the neuroprotective effect derived from reducing
oxidative stress and the apoptotic markers and was independent of the expression levels
of HIF-1α. Although the mechanisms of activation of NF-κB in response to hypoxia are
very complex and not well-known [22,24], our results indicate that, while the expression
of NF-κB depend on the occurrence of oxidative stress [52], the expression of HIF-1α
depends on the hypoxic stimulus, regardless of whether it generates oxidative stress or not.
Our results contrasted with those found by others [14,53], who reported an upregulation
of NF-κB in the neocortex and hippocampus after quantitative immunohistochemistry.
Two reasons could afford these contrasting results. On one hand, the differences in the
IHH preconditioning protocols (days of exposure and barometric pressure), the ASH
“dose” received by the exposed animals (6 h and 7% FiO2 vs. 3 h at 5% FiO2) and the
absence or presence of a reoxygenation period. On the other hand, the well-known dual
Int. J. Mol. Sci. 2021, 22, 5272 9 of 16
effects as survival or a pro-death factor in the nervous system described for NF-κB (see for
review [54]) could also play a role in the reported opposing findings.
3.4. Erythropoietin (EPO) Expression in the Brain
The EPO gene was identified as one of the genes activated by HIF-1α in response
to hypoxia [55]. Initially, it was believed that the only function of EPO was to regulate
the number of erythrocytes in the blood, allowing maturation of erythrocyte precursors
by inhibiting apoptosis [56]. Over the past decade, it has been shown that EPO is also
induced by hypoxia in the central nervous system, acting in the brain as an antiapoptotic,
antioxidant, anti-inflammatory, neuroprotective and neurotrophic factor [57,58]. In this
work, we have found that EPO levels were significantly increased in all groups exposed to
hypoxia, matching the increases in HIF-1α (Figure 3). It is noteworthy that EPO levels were
higher in IHH-exposed animals’ brains, with the highest significant differences compared
to NOR in the IHH+ASH group, indicating that IHH preconditioning favored the synthesis
of EPO [59]. Moreover, the IHH+ASH group showed significantly higher EPO expression
than ASH and IHH. As we have suggested recently, the neuroprotective effect of EPO is
associated with increases in antioxidant activity (Figure 1, Table 1) [60] and attenuates
apoptosis [61] (Figures 2 and 3). This demonstrates that EPO would act as a powerful
antioxidant allowing the neurons to regulate their intracellular redox condition [62] and
suggesting that increased EPO levels in the brain after hypoxia exposure is a potential
approach for promoting neuronal survival in vivo.
EPO can accomplish its protective role by targeting components common to many
different neurodegenerative pathways, which results in a plethora of different actions [63].
Mechanistically, it has been proposed that EPO action takes place through multiple sig-
naling pathways that can lead to tissue repair and cell protection [64]. These signaling
pathways increase the expression of antiapoptotic proteins of the Bcl-2 family, reducing
the release and expression of the main markers of the intrinsic mitochondrial apoptotic
pathway, such as cytochrome c and caspase-3, the main executioner of the mitochondrial
apoptotic pathway [19,63]. The integrity of mitochondria allows maintaining its redox
state, and, in consequence, the mitochondria ceases to be the main source of ROS, avoiding
the appearance of oxidative stress. Thus, the high levels of EPO found in our study in
the IHH+ASH group would justify the neuroprotective effect against oxidative stress and
apoptosis that are also deduced from our results.
3.5. Astrocytes
Since astrocytes have been considered specialized cells in detecting the decrease in
oxygen availability in the brain [25], we considered it interesting to investigate how these
cells may respond to ASH and the effects that preconditioning could elicit on them. Astro-
cytes are the most abundant glial cells involved in virtually every function of the central
nervous system, and the reciprocal interactions between glia and neurons are essential for
many critical functions in health and disease in the brain [65–67]. Astrocytes respond to all
forms of brain insults by a process commonly referred to as reactive astrogliosis, charac-
terized by the hypertrophy of their cell bodies and cell extensions and the upregulation
of intermediate filament proteins, such as glial fibrillary acidic protein (GFAP). This is a
process normally associated with beneficial consequences. However, it can lead to harmful
effects under specific conditions, changing their phenotype from a resting to a reactive form
after a finely graded continuum of changes that range from reversible alterations in gene
expression and cell hypertrophy to scar formation [67,68]. Our results show important
changes in the phenotype of astrocytes characterized by an increased expression of GFAP
protein in the hippocampal CA1 area in response to hypoxia (Figures 4 and 5B). Moreover,
hypertrophy in cell bodies and cell process length reduction was observed in ASH. In this
group, astrocyte morphology is compatible with what is defined as severe diffuse reactive
astrogliosis, while in IHH+ASH, astrocytes’ condition with abundant extensions could be
classified as mild to moderate astrogliosis. In the hippocampus, compared to NOR animals,
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hypoxic preconditioning caused a phenotype of reactive forms that expressed GFAP. Since
the existence of astrocytes that do not express detectable levels of GFAP has been described,
our results based on the detection of this protein do not allow us to distinguish whether the
IHH induced astrocyte proliferation or if it simply underwent increased GFAP expression
that was not detected in NOR. However, support for astrocyte proliferation can be derived
from previous work in the hippocampus dentate gyrus [69]. These authors suggested that
the neuroprotective effect observed in preconditioned rats, exposed to three sessions of
intermittent hypoxia and a subsequent ASH session, was stimulated by the neurogenesis
observed after immunohistochemistry for NeuroD2 transcription factor.
In conclusion, hypoxic preconditioning with a protocol of intermittent hypobaric
hypoxia had neuroprotective effects on acute severe hypoxia-induced oxidative injury
by reducing oxidative stress and inhibiting the apoptotic cascade, which was mediated
by NF-κB downregulation and EPO upregulation. Moreover, important changes were
found in the phenotype of astrocytes in the hippocampal CA1 area in response to hypoxia.
In animals exposed to acute severe hypoxia, these cells showed soma hypertrophy and
process length reduction compatible with severe diffuse reactive astrogliosis. The protocol
of hypoxic preconditioning also ameliorated this pathological astrocyte phenotype by
reducing the astrogliosis to mild or moderate.
4. Materials and Methods
4.1. Animals and Experimental Groups
Forty-four adult male Sprague-Dawley rats (Harlan Ibérica, Barcelona, Spain) weigh-
ing between 230 and 250 g were used for this study. The animals were maintained at
22 ± 1 ◦C with light/dark cycles of 12 h and had free access to food and water. Experimen-
tal procedures were conducted following the European Community Council Directive no.
86/609/EEC with the approval of the Ethical Institutional Committee on Animal Care and
Research of the University of Barcelona. Every effort was made to reduce the number of
animals and minimize animal suffering during the experiment.
Animals were randomly divided into four groups (Figure 6). (1) Group NOR (nor-
moxic), which could be considered the control group, consisted of animals maintained in
normoxic conditions (sea level) throughout the same time as the intervened animals. (2)
Group ASH (acute severe hypoxia group) was comprised of animals exposed to normo-
baric hypoxia in a chamber with a continuous flow of a hypoxic gas mixture of 93% N2
and 7% O2 for a unique and continuous session that lasted for 6 h. ASH animals were
killed by decapitation immediately after the exposure to hypoxia without giving time for
reoxygenation. (3) Group IHH (intermittent hypobaric hypoxia) included animals exposed
to hypobaric hypoxia for 8 consecutive days for 4 h sessions per day. A hypobaric chamber
with a capacity of 136 L made of polymethyl methacrylate plastic was used to simulate
an altitude of 4000 m. A relative vacuum (low-pressure) into the chamber was produced
by a rotational vacuum pump (TRIVAC D5E; Leybold, Köln, Germany) by regulating a
constant airflow rate of 2 L/h. Inner pressure was controlled by two differential pressure
sensors (ID 2000; Leybold) connected to a vacuum controller (Combivac IT23, Leybold,
Köln, Germany) driving a diaphragm pressure regulator (MR16, Leybold, Köln, Germany).
(4) Group IHH+ASH consisted of rats exposed to the intermittent hypobaric hypoxia pro-
tocol followed by the exposure to the normobaric acute severe hypoxic session. After the
hypoxic insult, animals were immediately killed by decapitation without giving time for
reoxygenation.
Brain extraction protocol using an ice-cold isotonic saline solution (0.154 M KCl),
sample storage at −80 ◦C and hemisphere processing for oxidative stress and Western blot
analyses were completed as previously described [28].
Int. J. Mol. Sci. 2021, 22, 5272 11 of 16
Int. J. Mol. Sci. 2021, 22, x FOR PEER REVIEW 11 of 16 
 
 
Forty-four adult male Sprague-Dawley rats (Harlan Ibérica, Barcelona, Spain) weigh-
ing between 230 and 250 g were used for this study. The animals were maintained at 22 ± 
1 °C with light/dark cycles of 12 h and had free access to food and water. Experimental 
procedures were conducted following the European Community Council Directive no. 
86/609/EEC with the approval of the Ethical Institutional Committee on Animal Care and 
Research of the University of Barcelona. Every effort was made to reduce the number of 
animals and minimize animal suffering during the experiment. 
Animals were randomly divided into four groups (Figure 6). (1) Group NOR 
(normoxic), which could be considered the control group, consisted of animals main-
tained in normoxic conditions (sea level) throughout the same time as the intervened an-
imals. (2) Group ASH (acute severe hypoxia group) was comprised of animals exposed to 
normobaric hypoxia in a chamber with a continuous flow of a hypoxic gas mixture of 93% 
N2 and 7% O2 for a unique and continuous session that lasted for 6 h. ASH animals were 
killed by decapitation immediately after the exposure to hypoxia without giving time for 
reoxygenation. (3) Group IHH (intermittent hypobaric hypoxia) included animals ex-
posed to hypobaric hypoxia for 8 consecutive days for 4 h sessions per day. A hypobaric 
chamber with a capacity of 136 L made of polymethyl methacrylate plastic was used to 
simulate an altitude of 4000 m. A relative vacuum (low-pressure) into the chamber was 
produced by a rotational vacuum pump (TRIVAC D5E; Leybold, Köln, Germany) by reg-
ulating a constant airflow rate of 2 L/h. Inner pressure was controlled by two differential 
pressure sensors (ID 2000; Leybold) connected to a vacuum controller (Combivac IT23, 
Leybold, Köln, Germany) driving a diaphragm pressure regulator (MR16, Leybold, Köln, 
Germany). (4) Group IHH+ASH consisted of rats exposed to the intermittent hypobaric 
hypoxia protocol followed by the exposure to the normobaric acute severe hypoxic ses-
sion. After the hypoxic insult, animals were immediately killed by decapitation without 
giving time for reoxygenation. 
 
Figure 6. Experimental design and hypoxia exposure protocols. Animal experimental groups are abbreviated as NOR 
(normoxic), maintained at sea level conditions for the whole experiment; ASH (acute severe hypoxia), exposed to normo-
baric hypoxia at 7% O2 for a single 6 h continuous session; IHH (intermittent hypobaric hypoxia) exposed to hypobaric 
hypoxia (4000 m) for 8 consecutive days for 4 h sessions per day; and IHH+ASH, exposed to the intermittent hypobaric 
hypoxia protocol followed by a single session of acute normobaric hypoxia. Brain extraction was carried out after 6 h of 
normoxia in NOR and IHH or immediately after 6 h of acute hypoxia in ASH and HII+ASH. Yellow boxes and arrows 
indicate time spent in normoxia; red boxes are acute normobaric hypoxia sessions, and blue boxes time spent in hypobaric 
hypoxia. 
Figure 6. Experimental design and hypoxia exposure protocols. Animal experimental groups are
abbreviated as NOR (normoxic), maintained at sea level conditions for the whole experiment; ASH
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4.2. Oxidative Stress Assays
4.2.1. Measurement of Oxidant Activity in the Brain
Lipid peroxidation was assessed using thiobarbituric acid-reactive substances (TBARS)
as indicators, following Mihara and Uchiyama [70]. Advanced oxidation protein products
(AOPP) were determined spectrophotometrically according to Barsotti et al. [71], and
nitric oxide species (NOx) were monitored by a colorimetric assay (Cayman Chemical,
Ann Arbor, MI, USA) as described by Castillo et al. [72]. A detailed description of all
these methods for measuring oxidant activity in the brain can be found in Coimbra-Costa
et al. [28].
4.2.2. Measurement of Antioxidant Activity in the Brain
Glutathione system. Reduced (GSH) and oxidized (GSSG) glutathione concentrations
were measured in brain extracts obtained using the procedure described by [73]. Samples
were homogenized in a cold 1:1 mixture (pH 6.8) of 0.1 M phosphate, 5 mM EDTA and 10%
metaphosphoric acid. Later on, the homogenates were incubated in ice for 30 min, cen-
trifuged at 100,000× g for 30 min, and the resulting supernatant was used to determine GSH
and GSSG with the fluorescent probe ophthalaldehyde (OPA). To avoid interference, the
aliquots for GSSG determination were previously incubated with N-ethylmaleimide, which
reacts with GSH to produce a form that lacks luminescence. After 15 min of incubation
with OPA, fluorescence was determined at 420 nm (excitation 350 nm). For determining
glutathione reductase (GR) and glutathione peroxidase (GPx) activities, the tissue was
homogenized by sonication in a cold buffer (pH 7.5) containing 50 mM NaH2PO4, 1 mM
EDTA. Subsequently, homogenates were centrifuged at 10,000× g for 10 min at 4 ◦C. The
resulting supernatant was used to measure GR and GPx activities using a Cayman kit at
340 nm (no. 703202 and no. 703102, Cayman Chemical, Ann Arbor, MI, USA).
Superoxide dismutase (SOD) activity. The brain tissue was homogenized by sonication
in a cold buffer (pH 7.5) containing 50 mM NaH2PO4, 1 mM EDTA and the homogenates
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were centrifuged at 600× g for 10 min at 4 ◦C. SOD activity was measured from the
supernatant at 450 nm using an Arbor kit (no. K028-H1, Arbor assays, Ann Arbor, MI,
USA).
4.3. Western Blotting
The brain hemispheres were homogenized in an ice-cold lysis buffer (pH 7.4) contain-
ing 50 mM Tris-HCl, 150 mM NaCl, 1% DOC, 0.1% SDS, 1% Triton X 100, and a protease
inhibitor cocktail (1:20) (sc-29130, Santa Cruz Biotechnology, Santa Cruz, CA, USA). Sub-
sequently, the homogenates were centrifuged for 10 min at 12,000× g, and the proteins
(50 µg) were electrophoresed and separated on 8%, 10% and 15% SDS–PAGE (Bio-Rad,
Hercules, CA, USA) and transferred to nitrocellulose membranes (Whatman® Schleicher
& Schuell, Keene, NH, USA). Urea-SDS gels were used to improve the resolution of the
proteins of low molecular weight [74]. The membranes were blocked in a solution contain-
ing 5% non-fat milk powder in a Tris-buffered saline (pH 7.6) containing 150 nM NaCl,
20 nM Tris-HCl and 0.05% Tween-20 for 1.5 h at room temperature and then thoroughly
incubated with the following primary antibodies (sc: Santa Cruz Biotechnology, Santa
Cruz, CA, USA): β-actin (sc-47778), cytochrome c (sc-13561), apoptosis-inducing factor
(AIF, sc-9416), hypoxia-inducible factor 1-alpha (HIF-1α, sc-10790), nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-κBp50, sc-33022), and erythropoietin (EPO,
sc-795216). Anti-cleaved caspase-3 antibody #9661 from Cell Signaling Technology (Dan-
vers, MA, USA) was used to assess the expression levels of cleaved caspase-3. β-actin was
used as a load control of the amount of sample protein. After several washes with TBST,
the membranes were incubated for 1.5 h at room temperature, with gentle stirring, with
the following horseradish peroxidase-conjugated secondary antibodies: goat anti-rabbit
IgG-HRP (111-035-003 Jackson Immuno Research, West Grove, PA, USA), goat anti-mouse
IgG-h+I HRP (A090-116P, Bethyl Laboratories, Montgomery, TX, USA), and rabbit anti-Goat
IgG-HR (sc-2768, Santa Cruz Biotechnology, Santa Cruz, CA, USA). Finally, membranes
were developed using a Thermo Scientific kit (Fisher Scientific, Waltham, MA, USA), and
bands were visualized on X-ray film (Kodak, Rochester, NY, USA). Densitometric analysis
was carried out using ImageJ software (NIH, Bethesda, MD, USA).
4.4. Immunohistochemistry
Five rats per group were anesthetized with ketamine/xylazine and fixed by intrac-
ardiac perfusion with a 0.1 M phosphate buffer (pH 7.4). The brains were obtained and
frozen after cryoprotecting them in a 30% sucrose solution. They were frozen and stored
until sectioned with a cryostat (Leica Microsystems, Wetzlar, Germany). Immunohisto-
chemistry was performed as described previously [75] in coronal sections of the Cornu
ammonis (CA1) hippocampal zone, and images were obtained with a microscope (Olympus
BX-61, Tokyo, Japan). Images of slides processed for GFAP immunohistochemistry were
analyzed with ImageJ (Rasband) software at 500 × magnification. The morphology of
GFAP-immunoreactive astrocytes was assessed quantitatively, measuring soma areas and
process lengths. The intensity of the astrocyte GFAP immune staining was expressed as a
percentage increase of the background stain of each slide.
4.5. Statistical Analysis
Statistical Package for Social Sciences (SPSS) software (v. 13.0, IBM, Armonk, NY, USA)
was used for statistical analyses. After testing normality and homoscedasticity, one-way
ANOVAs, with post hoc Bonferroni’s multiple comparison tests, were run for all-group
comparisons. p-values are given in Figures and Table as indicated in their legends.
5. Conclusions
This research demonstrates that intermittent respiratory hypoxia induces neuroprotec-
tive responses that prevent damage to brain cells, opening the possibility to apply hypoxic
preconditioning protocols to the whole organism for therapeutic purposes.
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Abbreviations
AIF Apoptosis-inducing factor
AOPP Advanced oxidation protein products
ASH Acute severe hypoxia
CA1 Hippocampus Cornu ammonis area 1
CNS Central nervous system
EPO Erythropoietin






IHH Intermittent hypobaric hypoxia
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells
NOR Normoxic
NOx Nitric oxide species
ROS Reactive oxygen species
SOD Superoxide dismutase
TBARS Thiobarbituric acid reactive substances (lipid peroxidation)
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